/
DCF Valuation
Base-case fair value
$5.77
Intrinsic $7.69 · 25% MOS
Current price: $16.28
Base-case summary
Our base-case DCF for Amneal Pharmaceuticals, Inc. (AMRX) projects 10 years of free cash flow growth at 4.4% for years 1–5 and 2.2% for years 6–10, anchored to 4.4% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $241M in trailing free cash flow, this produces an intrinsic value of $7.69 per share. A 25% safety margin gives a fair value of $5.77, suggesting the stock is currently 65% overvalued against the $16.28 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$241M
Cash & equivalents
$198M
Total debt
$2.6B
Shares outstanding
319M